[Informe de investigación] El tamaño del mercado de tecnología de bioprocesos se valoró en 30.897,49 millones de dólares en 2022 y se prevé que alcance los 77.090,05 millones de dólares en 2028; se estima que registrará una CAGR del 16,8% entre 2023 y 2028.
Punto de vista del analista
Las ventajas del bioproceso son el uso de menores presión, temperaturas más bajas y niveles de pH más propicios, y todo el proceso es renovable. Aumento del gasto en I+D para introducir nuevos compuestos farmacológicos y aumento de la prevalencia de enfermedades crónicas. Las políticas regulatorias estrictas son los factores más impactantes responsables del crecimiento influyente del mercado de tecnología de bioprocesos. Además, la introducción de tecnologías avanzadas de bioprocesos brinda una oportunidad de mercado lucrativa para que el mercado en general crezca exponencialmente durante el período de pronóstico. Además, la aparición de la citometría de flujo en tiempo real automatizada (ART-FCM) actúa como una tendencia futura para que el mercado crezca durante 2023-2028. Según la segmentación descrita en el informe, basada en el tipo de segmento, el bioproceso de medios de cultivo celular representa la mayor proporción; Asimismo, se prevé que el bioproceso de cromatografía registre la CAGR más alta durante el período de pronóstico (2023-2028). Además, por modalidad, el segmento de un solo uso representará una parte considerable de la tecnología de bioprocesos durante el período de pronóstico. En términos de usuario final, las empresas biofarmacéuticas’ El segmento dominará el crecimiento del mercado de tecnología de bioprocesos durante el período de pronóstico.
La tecnología de bioprocesos es una parte crítica de la biotecnología que se ocupa de procesos que combinan materia viva o sus componentes. con nutrientes que producen productos químicos, reactivos y bioterapéuticos especiales. Las diferentes etapas asociadas con la tecnología de bioprocesos involucran la preparación de sustratos y medios, la selección y optimización de biocatalizadores, la producción en volumen, el procesamiento posterior, la purificación y el procesamiento final. La tecnología de bioprocesos se utiliza ampliamente, desde alimentos y productos farmacéuticos hasta combustibles y productos químicos.
Perspectivas estratégicas
Perspectivas del mercado
Crecimiento Gastos en I+D para introducir nuevos compuestos farmacológicos
Las empresas farmacéuticas están gastando enormes sumas de dinero en I+D para introducir nuevas moléculas con mayor potencia médica y comercial para diversas aplicaciones terapéuticas. En el año fiscal 2019/2020, 16 empresas farmacéuticas llegaron a la lista de las 50 principales empresas del mundo en términos de inversión total en I+D. Novartis, Roche, Johnson & Johnson, Merck &Amp; Co, GlaxoSmithKline y Pfizer se encuentran entre las 10 principales empresas del mundo con altas inversiones en I+D.
Inversiones en I+D de las principales empresas farmacéuticas
< table class="tabla tabla con borde de tabla sombra con rayas g-rep-c-table" border="1" cellpacing="0" cellpadding="0">Empresa< /p>
Inversión en I+D en 2022 (millones de dólares)
Inversión en I+D en 2021 (millones de dólares)< /p>
Gilead Sciences Inc
27,305
Bristol-Myers Squibb Co
46,159
46,385
Amgen Inc.
26,323
25.979
Pfizer
100.330
81.288
Merck & Co
59.283
48.704
58,054
56,197
Nota: Las tasas de conversión de moneda se han considerado siempre que sea necesario.
Fuente: Informes anuales de empresas y análisis de Insight Partners
La expiración de las patentes de moléculas de gran éxito, un número limitado de productos potenciales en proceso y la creciente demanda de productos biológicos han llevado a las empresas a adoptar tecnologías novedosas, como tecnologías de bioprocesamiento de un solo uso, para facilitar un proceso de entrega rápido y rentable para los productos. Los fabricantes de sistemas y componentes de un solo uso suelen producir y ensamblar productos en salas limpias para garantizar que no introduzcan partículas nocivas ni endotoxinas en un bioproceso. Por tanto, se realizan grandes inversiones en I+D para introducir nuevos compuestos farmacológicos y ayudar al desarrollo de tecnologías de bioprocesamiento; estas tecnologías apoyan las capacidades emergentes de biofabricación y la interoperabilidad relacionada de materias primas, biorreactores y operaciones unitarias.
Información basada en tipos
Según el tipo, El mercado de tecnología de bioprocesos se segmenta en bioprocesos de medios de cultivo celular, bioprocesos de cromatografía, consumibles y productos. accesorios y otros. El segmento de bioprocesos de medios de cultivo celular tuvo la mayor participación de mercado de tecnología de bioprocesos en 2022, mientras que se prevé que el bioproceso de cromatografía registre una CAGR más alta durante el período de pronóstico (2023-2028).
< h3>Información basada en modalidadesSegún la modalidad, el mercado global de tecnología de bioprocesos se divide en uso único y uso múltiple. El segmento de uso único representó una mayor participación de mercado para la tecnología de bioprocesos en 2022. Se espera que el segmento de uso múltiple crezca a una tasa compuesta anual más alta durante el período de pronóstico.
Usuario final -Información basada en
En términos de usuario final, el mercado de tecnología de bioprocesos se clasifica en académicos y académicos. instituciones médicas, empresas biofarmacéuticas, laboratorios de investigación y otros. El segmento de empresas biofarmacéuticas tuvo la mayor cuota de mercado en 2022, mientras que el sector académico y empresarial fue el más importante. Se espera que las instituciones médicas registren una CAGR más alta durante el período de pronóstico.
Mercado de tecnología de bioprocesos, por tipo: 2022 y 2028
Análisis regional
América del Norte dominó el mercado de tecnología de bioprocesos y representó la participación máxima. El crecimiento del mercado de tecnología de bioprocesos en esta región se atribuye a la presencia de grandes actores que lanzan productos innovadores (particularmente relacionados con la tecnología de bioprocesos), la creciente introducción de productos en la región y los avances tecnológicos en la tecnología de bioprocesos. En América del Norte, EE.UU. registra la cuota máxima de tecnología de bioprocesos. Según el informe de la Administración de Alimentos y Medicamentos (FDA), más de 30 millones de personas en los EE. UU. padecen aproximadamente 7000 enfermedades raras, lo que representa afecciones potencialmente mortales con pocas opciones de tratamiento. El desarrollo de fármacos, productos biológicos y dispositivos para el tratamiento de enfermedades raras es un desafío debido a la falta de comprensión de la historia de las enfermedades raras y a la dificultad para realizar ensayos clínicos. Por lo tanto, el crecimiento de las tecnologías de bioprocesos, como las terapias genéticas y celulares (CGT) y los productos farmacéuticos especializados, representa un cambio radical en el tratamiento de enfermedades raras. Por ejemplo, los CGT han revelado importantes beneficios para la salud que los medicamentos formulados para el tratamiento de enfermedades raras. En los EE. UU., están en marcha más de 900 solicitudes de nuevos medicamentos en investigación (IND) dirigidos a productos de terapia génica. Además, la FDA aprueba anualmente entre 10 y 20 terapias genéticas. Asimismo, en agosto de 2022, la FDA aprobó el "Zynteglo (betibeglogene autotemcel)" de Bluebird Bio. Fue la aprobación de fármaco de aplicación única más cara en los EE. UU. destinada al tratamiento de un trastorno neurológico poco común: la adrenoleucodistrofia cerebral (CALD).
Del mismo modo, la región de Asia Pacífico representará la CAGR más alta para el mercado de tecnología de bioprocesos. En la región de Asia Pacífico, China tendrá una participación de mercado considerable en el mercado de tecnología de bioprocesos. La capacidad de bioprocesamiento a nivel mundial ha aumentado a un promedio del 12 % desde la última década, según el informe del índice de bioinstalaciones principales de BioPlan Associates y de la base de datos de biofabricantes. China está bien posicionada como participante global en los mercados de medicamentos de moléculas pequeñas y grandes, ocupando la segunda y tercera posición, respectivamente, a nivel mundial. Además, China alberga a varios desarrolladores de terapia celular y genética debido a la base de organizaciones de fabricación y desarrollo por contrato (CDMO) de China, que representan ~25% de la capacidad de bioproducción del país. Por lo tanto, China tiene considerables capacidades de biofabricación, pero un estricto cumplimiento de los estándares globales GMP que generan confianza en la seguridad y eficacia de los productos biológicos.
País< /p> | Instalación de biomanufactura (L) | < p>Capacidad global (%) | CAGR de capacidad estimada (%) | China | 1,77 millones < /td> | 10.2 | 15-20 
Report CoverageRevenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends 
Segment CoveredThis text is related 
Regional ScopeNorth America, Europe, Asia Pacific, Middle East & Africa, South & Central America 
Country ScopeThis text is related Frequently Asked Questions
What is the regional market scenario of the bioprocess technology market?
Global bioprocess technology market is segmented by region into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. In North America, the U.S. held the largest market share for bioprocess technology market. The US is expected to hold the largest share in the bioprocess technology market during the forecast period. The presence of top players and favorable regulations related to product approvals coupled with commercializing new products are the contributing factors for the regional growth. Additionally, the increasing number of technological advancements is the key factor responsible for the Asia Pacific regional growth in the coming years.
Who are the key players in the bioprocess technology market?
Merck KGaA, Sartorius AG, Thermo Fisher Scientific Inc, Corning Inc, STAMM Biotech, Lonza Group AG, Eppendorf SE, Repligen Corp, Danaher Corp, BioPharma Dynamics Ltd; are among the leading companies operating in the global bioprocess technology market
Which modality segment held the largest revenue (US$ Mn) in the bioprocess technology market?
The single use segment dominated the global bioprocess technology market.
Which product led the bioprocess technology market?
Based on type, cell culture media bioprocess took the forefront leaders in the worldwide market by accounting largest share in 2022 and is expected to continue to do so till the forecast period.
What are the driving factors for the bioprocess technology market across the globe?
The growing R&D spendings to introduce new drug compounds, and increasing prevalence of chronic diseases. However, stringent regulatory policies are restricting the market growth.
What is meant by the bioprocess technology market?
Bioprocessing is the process that utilizes complete living cells or components (e.g., bacteria, enzymes, and proteins) to obtain desired products. The process is commonly known as fermentation. The entire process is divided into three stages: upstream process, fermentation, and downstream process. The upstream process involves preparation of liquid media, separation of particulate and inhibitory chemicals through sterilization and air purification. Additionally, fermentation involves the conversion of substrate to obtain desired products through biological agents such as microorganisms. Furthermore, downstream processing involves separation of cells from the fermentation broth, purification and concentration of desired products and waste disposal or recycle method. The List of Companies - Bioprocess Technology Market
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain. Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team. For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise. A typical research interview fulfils the following functions:
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization. We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports. We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time. Related Reports
Jun 2023 Bioprocessing MarketSize and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Instruments, and Consumables and Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell and Gene Therapy, and Others), End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Jun 2023 Bioproduction MarketSize and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jun 2023 ELISA Diagnostic Test MarketSize and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Adoption (Human and Veterinary), Test Type (Sandwich ELISA, Indirect ELISA, Competitive ELISA, and Multiple & Portable ELISA), Application (Autoimmune Diseases, Infectious Diseases, Cancer Diagnosis, Protein Quantification, and Others), End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Veterinary Hospitals & Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Jun 2023 Swine Diagnostics MarketSize and Forecasts (2022 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type [Immunoassays Kits, PCR Kits, Hemagglutination Inhibition (HI), and Others], Sample Type (Blood, Oral Fluids, Nasal Swabs, Tissue Samples, and Others), Disease [African Swine Fever (ASF)/Classical Swine Fever (CSF), Respiratory Diseases, Porcine Circovirus, Porcine Epidemic Diarrhea, Swine Dysentery, and Others], End User (Veterinary Hospitals, Veterinary Clinics, and Other End Users), and Geography
Jun 2023 Microbial Identification Methods MarketSize and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Method (Genotypic, Phenotypic, and Proteotypic), Type (Bacterial Identification System, Microbial Enumeration System, Bacterial Resistance Identification Systems, Microbiology Analyzer, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
Jun 2023 Biopharmaceuticals MarketForecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
Jun 2023 GMP Cell Therapy Consumables MarketForecast to 2028 - COVID-19 Impact and Global Analysis by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research) |
